SCHEMBL30895142

SCHEMBL30895142

COCCn1ncc2ccc(NC(=O)OC(C)(C)C)c(OC)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
PDE10A Q9Y233 2/20 0.35
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ABL1 P00519 2/20 0.33
SRC P12931 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
ITGA4 P13612 1/20 0.33
ITGB7 P26010 1/20 0.33
ATM Q13315 1/20 0.33
NR1I2 O75469 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31017347 1.00 MAPK1 (0.38) MAPK1MAOAMAOBGSK3BDYRK1A
SCHEMBL25750456 0.90 GSK3B (0.37) MAPK1GSK3BDYRK1AKDM4ENPC1
SCHEMBL31017361 0.90 GSK3B (0.37) MAPK1GSK3BDYRK1AKDM4ENPC1
SCHEMBL25672474 0.88 MAPK1 (0.39) MAPK1GSK3BDYRK1AKDM4EABL1
SCHEMBL25758055 0.86 KDM4E (0.36) GSK3BDYRK1AKDM4ENPC1RAB9A
SCHEMBL30895063 0.86 MAPK1 (0.38) MAPK1GSK3BDYRK1AABL1SRC
SCHEMBL27199684 0.85 MAPK1 (0.43) MAPK1MAOAMAOBPDE10AKDM4E
SCHEMBL30860930 0.84 GSK3B (0.40) MAPK1GSK3BDYRK1AABL1HTT
SCHEMBL25756633 0.84 GSK3B (0.40) MAPK1GSK3BDYRK1AABL1HTT
SCHEMBL30895022 0.84 HTR2A (0.36) MAPK1GSK3BDYRK1AABL1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPK1 372/4885MAOA 2304/4885MAOB 1484/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPK1 372/4885MAOA 2304/4885MAOB 1484/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAPK1 372/4885MAOA 2304/4885MAOB 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.